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Abstract
Calciphylaxis is a lethal disorder seen in patients with end-stage renal disease and is characterized by
painful necrotic skin lesions. The pathophysiology is still unknown. Elevated calcium, phosphorous
and parathormone appear to play a role in causing small and medium sized vasculopathy. Diagnosis is
delayed, prognosis is poor and mortality remains high. In this article we describe the case of
calciphylaxis in a patient with chronic renal failure and multiple medical comorbidities, and discuss
diagnostic management, prognosis and treatment options.
Introduction
Calciphylaxis is rare disfiguring skin condition that is most
often associated with end-stage renal disease and long-
term dialysis. Calciphylaxis-related morbidity and mortal-
ity are significant. The case demonstrates the diagnostic
and therapeutic dilemmas associated with management of
such patients. The complexity of the patient’s history and
multiple medical comorbidities, attempted surgical inter-
ventions and inconclusive biopsy results complicates
diagnostic process. Close scrutiny of multiple physical
assessment findings, historical factors and test results were
required for correct diagnosis, assessment of prognosis
and treatment options.
Case presentation
A 78-year-old African American female was admitted with
multiple painful ulcers on the lower extremities and
possible septicemia. Her medical history included cor-
onary artery disease, peripheral vascular disease, end-stage
renal disease on hemodialysis for 7 months, insulin-
dependent diabetes, hypertension, hypothyroidism,
chronic obstructive pulmonary disease and asthma. Her
surgical history included thyroidectomy and left upper
extremity graft in October 2005 which failed to maturate
and patient did not follow up. Patient was admitted in
March 2006 for symptoms of worsening of lower
extremity swelling and paroxysmal nocturnal dyspnea
when her laboratory results showed BUN-141 mg/dl and
creatinine-8.1 mg/dl. Patient underwent fistulogram
which showed multiple high-grade stenosis. She had
internal jugular catheter placed at the time and was started
on daily hemodialysis. When she was discharged 6 days
later, her BUN was 33 mg/dl and creatinine was 5.4 mg/dl.
She was advised to follow with the dialysis center three
times weekly, however patient remained noncompliant
with intermittent dialysis. Since the September 2006
hospitalization as described on the case she was dialyzed
regularly on Tuesday, Thursday & Saturday. She also had
right lower extremity angiogram with an attempted right
superficial femoral arterectomy and angioplasty which
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wound debridements in the past 3-4 months. Drug
therapy included aspirin 81 mg daily, pentoxifylline
400 mg 3 times daily, lisinopril 40 mg daily, amlodipine
10 mg and minoxidil 2.5 mg daily, insulin 70/30 22 units
every morning and 12 units every evening, atorvastatin
40 mg daily, albuterol and atrovent inhalers as needed,
levothyroxine 150 mcg daily, PhosLo 2 caps 3 times daily,
cinacalcet 30 mg daily, colace 100 mg twice daily,
hydrocodone 500 mg as needed. Patient denied any
exposure to tobacco, ethanol, and intravenous drug abuse.
She had 2 children and lived with her sonand daughter-in-
law who are the primary caretakers. Family history
included chronic kidney disease, hypertension, coronary
artery disease and diabetes.
Six months prior to presentation, she was found to have
significant hyperparathyroidism (serum intact parathor-
mone of 1133 pg/ml [normal, 10-65]) and hypercalcemia
of 11.1 mg/dl [normal, 8.5-10.5]. Meanwhile, she devel-
oped 7 × 4 cm ulcer on the posterior aspect of right calf
after a burn which remained non-healing for more than 2
weeks. She complained of severe local pain and continued
developing multiple ulcerations on both lower extremi-
ties. Wound care and pain management was attempted as
outpatient. Admission followed due to worsening of
ulcerations and poor pain control. On admission, physical
examination revealed obese (Ht-154 cm, Wt-84 kgs,
BMI-35) African American female in distress due to pain
with marked abdominal adiposity, absent pedal pulses
and extensive lesions on the hips, buttocks, and proximal
thighs with surrounding erythema, induration and dark
eschar (Figure 1a & 1b). No other pertinent physical
findings were present. Laboratory studies showed serum
calcium of 8.6 mg/dl (normal, 8.5-10.5), serum
phosphorous of 3.7 mg/dl (normal, 2.5-5.0), calcium-
phosphorous product - 31.8, parathormone of 155 pg/ml
(normal, 10-65), urea of 35 mg/dl (normal, 7-20) and
creatinine of 4.3 mg/dl (normal, 0.8-1.3), alkaline
phosphatase-145 IU (normal, 70-230 IU), and serum
albumin-1.9 g/dl (normal, 3.5-5.5 g/dl).
X-ray of lower extremities revealed extensive arterial
calcifications within the femoral, popliteal artery and
smaller branches. Nuclear medicine scan of parathyroid
showed adenoma of the right lobe. With significant
multiple co morbidities of diabetes, peripheral vascular
disease and end stage renal disease, we considered the
possibilities of ischemic ulcers and superimposed infec-
tion. The patient underwent several investigations, includ-
ing a lower extremity angiogram with an attempted right
superficial femoral arterectomy and angioplasty which
failed because of severely calcified vessels and multiple
wound debridements in the past 3-4 months. Hypercoa-
gulable state with cryoglobulinemia was also ruled out,
with the results of protein C, protein S and antithrombin-3
being in the normal range.
A biopsy of the lower extremity ulcer demonstrated
circumferential vascular mural calcification affecting
small and medium sized blood vessels with degeneration
of elastic fibers and absence of inflammation (Figure 2).
During her hospitalization, despite attempts to control
deterioration (wound care, pain control, hemodialysis and
parenteral antibiotics), leg wounds and general condition
worsened over the next 3-4 weeks. She exhibited periodic
disorientation. Upon multiple discussions with the family
on different treatment options and overall poor prognosis,
the patient’s family opted for comfort care under Hospice.
Patient expired two days later.
Figure 1.
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Calciphylaxisisanabnormalskincalcificationfoundmostly
in end-stage renal disease patients who have secondary
hyperparathyroidism. The integumentary deterioration is
related tocalcificationofsofttissuesandbloodvessel walls,
causing cessation of blood supply. The process of calciphy-
laxis was originally described by Hans Selye in 1962
following experimental observations in animal models
[1]. As the process was considered to be one of ‘induced
hypersensitivity’, resulting in local calcification following
the two-step process of sensitizing and challenging (analo-
gous to anaphylaxis), it was termed calciphylaxis [2].
An estimated 1% of end-stage renal disease patients de-
velop calciphylaxis yearly, with a potential total prevalence
up to 4% of all end-stage renal disease patients [3]. Risk
factors include renal impairment, dialysis dependency,
females, obesity, warfarin use, hypercoagulable states,
diabetes mellitus, atherosclerosis, hypertension, protein
malnutrition andthosereceiving calciumsaltsandvitamin
D therapy. Calciphylaxis occurrence or severity is not
predicted on the type or duration of chronic renal failure,
the severity of hyperparathyroidism, or the degree of
parathyroid hormone elevation.
The pathogenesis of this disease remains elusive [4].
Hypercalcemia, hyperphosphatemia, and hyperparathyr-
oidism are frequently seen with calciphylaxis, but their
absence does not exclude the diagnosis. In patients with
end stage renal disease, positive calcium balance and use
of oral phosphate binders to combat osteodystrophy
accelerates uremic vasculopathy in the dialysis population
[5]. Exposure of vascular smooth muscle to uremic serum
or phosphorus in vitro increases osteopontin expression
causing the transformation of vascular smooth muscle
cells to an osteoblastic phenotype in the mechanism of
medial calcinosis. Endovascular fibrosis is the major cause
of ischemia while other proposed hypothesis include
luminal obliteration by calcium salts, thrombosis due to
acquired protein C deficiency, vasoconstrictor effect of
calcium and autonomic dysfunction. Role of protein C
deficiency in the pathogenesis of systemic calciphylaxis is
still unclear [4].
Microvascular calcification in the intima of small arteries
and, to a lesser extent, in the media is noted histologically.
The lumen of the vessels is thereby narrowed, and arterial
thrombosis is occasionally seen with and without signs of
recanalization. Complete vascular occlusion is rarely
noted. In consort with the distinctive mural calcification
is a superimposed intimal fibroblastic hyperplasia with
the presence of giant cells that appears to be the primary
cause of the ischemia [6]. This histologic feature in the
small arteries with a diameter of approximately 0.04 to
0.1 mm in uremics is almost pathognomonic for
calciphylaxis and can be easily differentiated from
atheromatosis and peripheral arterial occlusive disease.
The time period for the onset of symptoms of calciphylaxis
ranged from less than 1 month to as long as 12 years after
the onset of end-stage renal disease (median, 2 yr
9 months) [4]. The classical presentation starts with
painful purplish (violaceous) mottled skin lesions that
maybecome plaque like or nodular. They often progressto
non-healing ulcers with wound infection and eschar
formation, and usually develop gangrene. Involvement
of the lower extremities is almost universal. Preserved
peripheral pulses favor the diagnosis of calciphylaxis.
The diagnosis of calciphylaxis is based on clinical,
biochemical and histopathological features. Laboratory
values of calcium, phosphorous, calcium-phosphorous
product, parathormone, alkaline phosphatase, urea and
creatinine are likely to be significantly elevated. Radio-
graphy may reveal subperiosteal bone resorption and
‘pipe-stem’ pattern of vascular calcification. Bone scan may
reveal increased tracer accumulation in subcutaneous
tissue in a patient with end-stage renal disease and
calciphylaxis [7]. Tissue biopsy usually shows multiple
discrete foci of calcification within the adipose lobules, in
subcutaneous septa, and in the tunica media layer of
small-to medium-sized blood vessels. Factors associated
with poor prognosis include cutaneous ulcers, extensive
tissue involvement, previous renal transplant, proximal
lesions, a history of trauma and higher preoperative
leukocyte counts (over 20,000).
Differential diagnosis for similar ulcerations include vascu-
litis, systemic lupus erythematosus, cryoglobulinemia,
Figure 2.
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cholesterol emboli, Henoch-Schonlein purpura, homocys-
teinemia, heparin-associated gangrene, warfarin-induced
skin necrosis and bacterial endocarditis. Investigations
includingvasculitisscreen,estimationofcryoglobulinsand
cryofibrinogens, fibrin degradation products, antipho-
spholipid antibodies and Doppler assessment of limb
vessels need to be considered [8].
Diligent wound care, avoidance of trauma, and appro-
priate antibiotic usage together with nutritional support
and adequate pain control are important aspects of general
care of these patients. Wound care includes gentle
handling and moist wound dressing with material such
as petrolatum-impregnated gauze to minimize tissue
damage and local debridement. Sterile maggot therapy,
pentoxyfillin and hyperbaric oxygen is used to treat
ulcerated areas [9].
Medical management involves normalization of altered
calcium and phosphorous levels. Food high in calcium
and phosphorous must be limited. Calcium and alumi-
num-free phosphate binders such as renagel have been
found to be useful in the management of renal osteody-
strophy. Laboratory values have to be monitored so the
calcium-phosphorous product, parathormone level, total
protein and pre-albumin level stay within normal limits.
Increased frequency of haemodialysis too has been
employed as a management strategy.
Good pain relief is the most important and challenging
aspect of symptom control [10]. Severe pain, opioid
resistance, and the susceptibility of these patients to
opioid toxicity mandate a broad approach to analgesia.
Combination of an opioid, benzodiazepine, and ketamine
appears to give the best analgesia. Other options include
inhaled nitrous oxide, and potent parenteral anti-inflam-
matory agents such as ketorolac. The use of spinal
analgesia with local anesthetic agents has also been used
with limited effectiveness. Fentanyl analogs are a good
choice in these patients because of their hepatic clearance,
stability during dialysis, and lack of clinically active
metabolite accumulation.
Surgical treatment is only variably successful. Total
parathyroidectomy or parathyroidectomy with auto trans-
plantation is recommended for patients with hyperpar-
athyroidism [10]. Severe necrosis of extremities often
involves amputation.
Early involvement of a multidisciplinary palliative care
team is beneficial. Given the poor prognosis of calciphy-
laxis, the team also provides a bridge to terminal care as
the patient’s condition deteriorates [10].
Conclusion
Calciphylaxis is a potentially lethal syndrome seen in
patients with end-stage renal disease and secondary
hyperparathyroidism. It may, however, be associated with
other disease entities in the absence of renal or parathyroid
disease. A high index of suspicion, early intervention, and
an active multidisciplinary medical and surgical approach
are vital aspects of the management strategy.
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